<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364273</url>
  </required_header>
  <id_info>
    <org_study_id>B2F104300</org_study_id>
    <nct_id>NCT00364273</nct_id>
  </id_info>
  <brief_title>GSK159802 In Healthy Male Subjects And Asthmatics</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Profile of Single Inhaled Dry Powder Doses of GSK159802 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK159802 is a potent, inhaled, long acting selective beta-2-receptor agonist (LABA), which
      is being developed for once daily treatment of asthma and COPD as part of a combination
      product with a once daily inhaled corticosteroid and also as a standalone product for the
      treatment of COPD. Stimulation of the beta-2-agonist in the lung mainly relaxes bronchial
      smooth muscle cells which results in bronchodilation. Unwanted systemic side effects related
      with beta-2-agonist treatment such as tachycardia, tremor, hyperglycemia and hypokalemia are
      limited by local administration and also tend to show tachyphylaxis.

      The LABAs that are currently available (e.g., salmeterol, formoterol) require twice-daily
      administration, given their duration of action. Therefore, there is significant opportunity
      for a once-daily inhaled medication to improve patient compliance and overall disease
      management by providing sustained, 24-hour bronchodilation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2005</start_date>
  <completion_date type="Actual">July 6, 2006</completion_date>
  <primary_completion_date type="Actual">July 6, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability of single inhaled doses of GSK159802.</measure>
    <time_frame>Up to 71 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sGaw (Cohorts 1 and 2 only) and FEV1 Systemic &amp; urine pharmacokinetics of GSK159802 and SKF-91300 Heart rate, potassium, glucose, 12-lead ECG &amp; blood pressure</measure>
    <time_frame>Up to 71 days</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK159802</intervention_name>
    <description>GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.</description>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo administered using DISKUS inhaler.</description>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.</description>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2 : Cohort 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1 : Cohort 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4 : Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body mass index within the range 18.5-29.9 (kg/m2)

          -  Current non-smokers who have not used any tobacco products in the 6-month period
             preceding the screening visit and have a pack history of &lt; 10 pack years.

        Additional criteria for Cohorts 2 and 3 only (Asthmatic Patients):

          -  Subjects with a documented history of mild to moderate asthma, with the exclusion of
             other significant pulmonary disease

          -  Subjects with clinically stable asthma within the 4 weeks preceding the screening
             visit and with a screening pre-bronchodilator FEV1 greater than 60% and less than 90%
             predicted.

        During the screening visit, subjects must demonstrate the presence of reversible airway
        disease, defined as an increase in FEV1 of &gt; or equal to 12.0% over baseline and an
        absolute change of &gt; or equal to 300 mL within 30 minutes following 400 mcg salbutamol.

        Exclusion criteria:

          -  Any clinically relevant abnormality

          -  Subjects who have a screening haemoglobin values &lt; 11 g/dL

          -  The subject has participated in a clinical study with a New Chemical Entity (NCE)
             within the past 112 days or a clinical study with any other drug during the previous
             84 days

          -  Subjects with known hypersensitivity to salmeterol or salbutamol or any ingredients in
             their preparations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/B2F104300?search=study&amp;study_ids=B2F104300#rs</url>
    <description>Results for study B2F104300 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

